All IndicationsPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2
Myelodysplastic Syndromes
5
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
TRAW
Traws Pharma, Inc.
rigosertib sodium
GERN
Geron Corporation
Placebo
TRAW
Traws Pharma, Inc.
Oral rigosertib
LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LB-100
NVS
Novartis AG
decitabine
AGIO
Agios Pharmaceuticals, Inc.
Tebapivat
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| TRAW Traws Pharma, Inc. | rigosertib sodium | Phase 3 | — | — | — |
| GERN Geron Corporation | Placebo | Phase 3 | — | — | — |
| TRAW Traws Pharma, Inc. | Oral rigosertib | Phase 2 | — | — | — |
| LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC. | LB-100 | Phase 2 | — | — | — |
| NVS Novartis AG | decitabine | Phase 2 | — | — | — |
| AGIO Agios Pharmaceuticals, Inc. | Tebapivat | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.